A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study)

Conclusions.
The early introduction of EVR after KT did not increase the risk of WHC, showing good efficacy and safety profile.

Source: Transplantation - February 1, 2020 Category: Transplant Surgery Tags: Original Clinical Science—General Source Type: research